|
|
Editorial |
| GUEST EDITORS’ FOREWORD |
569 |
| Matthew H Liang, MD, MPH & Peter H Schur, MD
|
|
Full Article (PDF)
|
|
Papers |
| A conceptual framework for clinical trials in SLE and other multisystem diseases |
570 |
| Matthew H Liang,
Michael Corzillius,
Sang-Cheol Bae,
Paul Fortin,
John M Esdaile & Michal Abrahamowicz
|
|
Full Article (PDF)
|
|
| Development of an FDA guidance document for clinical trials in SLE |
581 |
| JN Siegel
|
|
Abstract
Full Article (PDF)
|
|
| The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weaknesses, and opportunities for improvement |
586 |
| EL Smith & RH Shmerling
|
|
Abstract
Full Article (PDF)
|
|
| World Wide Web: Opportunities, challenges, and threats |
596 |
| SM Edworthy
|
|
Abstract
Full Article (PDF)
|
|
| Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE) |
606 |
| Diane Ferland & Paul R Fortin
|
|
Abstract
Full Article (PDF)
|
|
| Sample size considerations for superiority trials in systemic lupus erythematosus (SLE) |
612 |
| Andrew D Moore & Lawrence Joseph
|
|
Abstract
Full Article (PDF)
|
|
| Equivalence trials in SLE research: issues to consider |
620 |
| Mimi Y Kim,
Jill P Buyon,
Michelle Petri,
Mary Louise Skovron & Roy E Shore
|
|
Abstract
Full Article (PDF)
|
|
| Response and remission criteria for clinical trials in lupus–what can we learn from other diseases? |
627 |
| M Schneider
|
|
Full Article (PDF)
|
|
| The SLICC/ACR damage index: progress report and experience in the field |
632 |
| DD Gladman & Murray B Urowitz
|
|
Abstract
Full Article (PDF)
|
|
| Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients |
638 |
| JD FitzGerald & JM Grossman
|
|
Abstract
Full Article (PDF)
|
|
| Quality of life and economic evaluation in SLE clinical trials |
645 |
| Caroline Gordon & Ann E Clarke
|
|
Abstract
Full Article (PDF)
|
|
| Responsiveness and sensitivity to change of SLE disease activity measures |
655 |
| M Corzillius,
P Fortin & G Stucki
|
|
Abstract
Full Article (PDF)
|
|
| Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials |
660 |
| Jim C Yen,
Carolyn Neville & Paul R Fortin
|
|
Abstract
Full Article (PDF)
|
|
| Ensuring reliability of clinical assessments for SLE trials |
671 |
| Rosalind Ramsey-Goldman & Karen W Hayes
|
|
Abstract
Full Article (PDF)
|
|
| Assessing disease activity in SLE patients during pregnancy |
677 |
| Jill P Buyon,
Kenneth C Kalunian,
Rosalind Ramsey-Goldman,
Michelle A Petri,
Michael D Lockshin,
Guillermo Ruiz-Irastorza & Munther Khamashta
|
|
Full Article (PDF)
|
|
| Classification and definition of major flares in SLE clinical trials |
685 |
| Michelle Petri,
Jill Buyon & Mimi Kim
|
|
Abstract
Full Article (PDF)
|
|
| Methodological issues of corticosteroid use in SLE clinical trials |
692 |
| M Corzillius & S-C Bae
|
|
Abstract
Full Article (PDF)
|
|
| Early stopping of clinical trials in lupus and other uncommon rheumatologic diseases |
698 |
| Michael P LaValley & David T Felson
|
|
Abstract
Full Article (PDF)
|
|
